TY - JOUR
T1 - The INTERPHONE study
T2 - Design, epidemiological methods, and description of the study population
AU - Cardis, Elisabeth
AU - Richardson, Lesley
AU - Deltour, Isabelle
AU - Armstrong, Bruce
AU - Feychting, Maria
AU - Johansen, Christoffer
AU - Kilkenny, Monique
AU - McKinney, Patricia
AU - Modan, Baruch
AU - Sadetzki, Siegal
AU - Schüz, Joachim
AU - Swerdlow, Anthony
AU - Vrijheid, Martine
AU - Auvinen, Anssi
AU - Berg, Gabriele
AU - Blettner, Maria
AU - Bowman, Joseph
AU - Brown, Julianne
AU - Chetrit, Angela
AU - Christensen, Helle Collatz
AU - Cook, Angus
AU - Hepworth, Sarah
AU - Giles, Graham
AU - Hours, Martine
AU - Iavarone, Ivano
AU - Jarus-Hakak, Avital
AU - Klaeboe, Lars
AU - Krewski, Daniel
AU - Lagorio, Susanna
AU - Lönn, Stefan
AU - Mann, Simon
AU - McBride, Mary
AU - Muir, Kenneth
AU - Nadon, Louise
AU - Parent, Marie Elise
AU - Pearce, Neil
AU - Salminen, Tiina
AU - Schoemaker, Minouk
AU - Schlehofer, Brigitte
AU - Siemiatycki, Jack
AU - Taki, Masao
AU - Takebayashi, Toru
AU - Tynes, Tore
AU - Van Tongeren, Martie
AU - Vecchia, Paolo
AU - Wiart, Joe
AU - Woodward, Alistair
AU - Yamaguchi, Naohito
N1 - Funding Information:
P Marks, Dr M Nelson, Dr S Omer, Mr N Phillips, Mr S Ross, Dr I Rothwell, Dr H Spokes, Dr J Straiton, Mr G Towns, Nr A Tyagi, Mr P Vanhille, Dr M Busby).This study was conducted with funding from the European Fifth Framework Program, ‘‘Quality of Life and Management of Living Resources’’ (contract QLK4-CT-1999901563) and the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers’ Forum and GSM Association. Provision of funds to the INTERPHONE study investigators via the UICC was governed by agreements that guaranteed INTERPHONE’s complete scientific independence. The terms of these agreements are publicly available at http://www.iarc.fr/ENG/ Units/RCAd.html/. The Australian centre was supported by the National Health and Medical Research Council (EME Grant 219129); Bruce Armstrong is supported by a University of Sydney Medical Foundation Program Grant and Julianne Brown by an Australian Postgraduate Award. The Cancer Council NSW and The Cancer Council Victoria provided most of the infrastructure for the project in Australia. The Canada-Montréal data collection was funded by a grant from the Canadian Institutes of Health Research (project MOP-42525). Dr. Siemiatycki had salary support from the Canada Research Chair programme. Dr. Parent had salary support from the Fonds de recherche en santé du Québec. The other Canadian centres were supported by a university-industry partnership grant from the Canadian Institutes of Health Research (CIHR), the latter including partial support from the Canadian Wireless Telecommunications Association. The CIHR university-industry partnerships program also includes provisions that ensure complete scientific independence of the investigators. D. Krewski is the NSERC/SSHRC/ McLaughlin Chair in Population Health Risk Assessment at the University of Ottawa. The Danish centre was supported by the Danish Cancer Society and the Finnish centre by the Emil Aaltonen Foundation and the Academy of Finland. Additional funding for the study in France was provided by l’Association pour la Recherche sur le Cancer (ARC: Contrat No. 5142) and three network operators (Orange, SFR, Bouygues Télécom). The funds provided by the operators represented 5% of the total cost of the French study and were governed by contracts guaranteeing the complete scientific independence of the investigators. In Germany additional funds were received from the German Mobile Phone Research Program (De-utsches Mobilfunkforschungsprogramm) of the German Federal Ministry for the Environment, Nuclear Safety, and Nature Protection; the Ministry for the Environment and Traffic of the state of Baden-Württemberg; the Ministry for the Environment of the state of North Rhine-Westphalia; the MAIFOR Program (Mainzer For-schungsforderungsprogramm) of the University of Mainz. The study conducted in Japan was fully funded by the Ministry of Internal Affairs and Communications of Japan. In New Zealand, funding was provided by the Health Research Council, Hawkes Bay Medical Research Foundation and the Cancer Society of New Zealand. The Swedish centre was also supported by the Swedish Research Council and the Swedish Cancer Society. Additional funding for the UK-North & UK-South studies was received from the Mobile Telecommunications, Health and Research (MTHR) program and the UK-North study received funding from the Health and Safety Executive, the Department of Health, the UK Network Operators (O2, Orange, T-Mobile, Vodafone, ‘3’) and the Scottish Executive.
PY - 2007/9
Y1 - 2007/9
N2 - The very rapid worldwide increase in mobile phone use in the last decade has generated considerable interest in the possible health effects of exposure to radio frequency (RF) fields. A multinational case-control study, INTERPHONE, was set-up to investigate whether mobile phone use increases the risk of cancer and, more specifically, whether the RF fields emitted by mobile phones are carcinogenic. The study focused on tumours arising in the tissues most exposed to RF fields from mobile phones: glioma, meningioma, acoustic neurinoma and parotid gland tumours. In addition to a detailed history of mobile phone use, information was collected on a number of known and potential risk factors for these tumours. The study was conducted in 13 countries. Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the UK using a common core protocol. This paper describes the study design and methods and the main characteristics of the study population. INTERPHONE is the largest case-control study to date investigating risks related to mobile phone use and to other potential risk factors for the tumours of interest and includes 2,765 glioma, 2,425 meningioma, 1,121 acoustic neurinoma, 109 malignant parotid gland tumour cases and 7,658 controls. Particular attention was paid to estimating the amount and direction of potential recall and participation biases and their impact on the study results.
AB - The very rapid worldwide increase in mobile phone use in the last decade has generated considerable interest in the possible health effects of exposure to radio frequency (RF) fields. A multinational case-control study, INTERPHONE, was set-up to investigate whether mobile phone use increases the risk of cancer and, more specifically, whether the RF fields emitted by mobile phones are carcinogenic. The study focused on tumours arising in the tissues most exposed to RF fields from mobile phones: glioma, meningioma, acoustic neurinoma and parotid gland tumours. In addition to a detailed history of mobile phone use, information was collected on a number of known and potential risk factors for these tumours. The study was conducted in 13 countries. Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the UK using a common core protocol. This paper describes the study design and methods and the main characteristics of the study population. INTERPHONE is the largest case-control study to date investigating risks related to mobile phone use and to other potential risk factors for the tumours of interest and includes 2,765 glioma, 2,425 meningioma, 1,121 acoustic neurinoma, 109 malignant parotid gland tumour cases and 7,658 controls. Particular attention was paid to estimating the amount and direction of potential recall and participation biases and their impact on the study results.
KW - Acoustic neurinoma
KW - Benign tumours
KW - Brain tumours
KW - Cancer
KW - Case-control
KW - Methods
KW - Mobile phones
KW - Parotid gland tumours
KW - Study design
UR - http://www.scopus.com/inward/record.url?scp=34548626804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548626804&partnerID=8YFLogxK
U2 - 10.1007/s10654-007-9152-z
DO - 10.1007/s10654-007-9152-z
M3 - Article
C2 - 17636416
AN - SCOPUS:34548626804
SN - 0393-2990
VL - 22
SP - 647
EP - 664
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
IS - 9
ER -
